Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims are directly supported by the provided label excerpts (notably grapefruit juice–CYP3A4 interaction increasing atorvastatin plasma concentrations, and statin skeletal muscle/liver risk concepts). Several additional claims are not supported by the provided excerpts or appear inaccurate relative to them (notably bleeding risk, grapefruit juice cardiovascular benefits, HDL improvement by grapefruit juice, antioxidant/inflammation claims, and the absolute “no safe amount” statement).
Category Scores
Accurate Statements
Grapefruit juice contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).
Label 7.2 Grapefruit Juice: "Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day)."
Inhibition of the enzyme responsible for metabolizing Lipitor by grapefruit juice can increase Lipitor levels in the bloodstream.
Label 7.2 Grapefruit Juice: "can increase plasma concentrations of atorvastatin" (mechanism framed as CYP3A4 inhibition).
Elevated levels of Lipitor in the bloodstream can lead to muscle damage, pain, and weakness.
Label 5.1 Skeletal Muscle: "rare cases of rhabdomyolysis" and "Atorvastatin, like other statins, occasionally causes myopathy" and risk increased with certain drugs; label also supports myopathy/rhabdomyolysis as adverse outcomes related to increased exposure in interacting contexts.
Grapefruit juice can increase the risk of liver damage, particularly in patients with pre-existing liver conditions.
Label 5.2 Liver Dysfunction: statins "associated with biochemical abnormalities" and contraindication includes "Active liver disease or unexplained persistent transaminase elevations"; while the excerpt does not explicitly connect grapefruit to liver damage, it supports liver risk in general for statins and the relevance of liver disease.
Unsupported Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
The provided excerpts do not explicitly state that Lipitor is used to lower cholesterol levels in blood (though mechanism/clinical pharmacology and hyperlipidemia section imply lipid lowering). No direct label excerpt supports this exact phrasing.
Lipitor works by inhibiting cholesterol production in the liver, reducing low-density lipoprotein (LDL) cholesterol in the bloodstream.
The provided excerpts describe inhibition of HMG-CoA reductase (mechanism) and show LDL lowering (e.g., Label 14.2 and 12.1/14.2), but the excerpt does not explicitly state "inhibiting cholesterol production in the liver" or match the exact claim wording.
Consuming grapefruit juice with Lipitor can increase the risk of adverse effects.
Label excerpt supports increased plasma concentrations (7.2) but does not explicitly state "increase the risk of adverse effects".
The interaction between grapefruit juice and Lipitor can increase the risk of bleeding.
The provided label excerpts do not mention bleeding/hemorrhage as a grapefruit juice interaction or as a general interaction-related adverse effect for this specific claim.
Grapefruit juice can increase the risk of liver damage, particularly in patients with pre-existing liver conditions.
Label excerpt discusses liver dysfunction risk and contraindication for active liver disease, but the provided excerpts do not explicitly tie grapefruit juice to increased hepatotoxicity risk.
The increased risk of bleeding with grapefruit juice and Lipitor may be particularly relevant in patients taking anticoagulant medications.
No provided label excerpt supports a grapefruit juice + anticoagulant bleeding risk relationship.
Grapefruit juice may improve cardiovascular health.
No provided label excerpt supports cardiovascular benefit of grapefruit juice.
Grapefruit juice has been shown to improve lipid profiles, including increasing high-density lipoprotein (HDL).
No provided label excerpt supports grapefruit juice improving lipid profiles or increasing HDL.
Grapefruit juice contains antioxidants that may help protect against oxidative stress and inflammation.
No provided label excerpt supports antioxidant/oxidative stress/inflammation claims about grapefruit juice.
A study reported grapefruit juice can increase the bioavailability of Lipitor by up to 50%.
No provided label excerpt includes a "up to 50%" bioavailability figure for grapefruit juice.
Another study reported grapefruit juice increases the risk of muscle damage and liver damage in patients taking Lipitor.
The provided label excerpts do not provide study results stating increased risk of muscle damage and liver damage due to grapefruit juice.
There is no safe amount of grapefruit juice that can be consumed with Lipitor.
Label excerpt provides a threshold for excessive grapefruit juice consumption (>1.2 liters/day) but does not state "no safe amount".
It is not recommended to consume grapefruit juice with Lipitor without consulting a healthcare provider first.
The provided label excerpt specifies mechanism and emphasizes increased concentrations with excessive intake, but the excerpts do not include a recommendation to consult a provider or an explicit "not recommended without consulting" statement.
Contradictions
Important Omissions
Clear label-consistent guidance on grapefruit juice amount/avoidance (e.g., the label’s reference to "especially with excessive grapefruit juice consumption (>1.2 liters per day)") rather than absolute statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some statements are consistent with increased atorvastatin plasma concentrations from grapefruit juice (supported). However, several claims introduce unsupported risks (e.g., bleeding risk, specific magnitudes like 50% bioavailability) and absolute counseling statements ("no safe amount") that are not supported by the provided excerpts, potentially leading to over- or misinterpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple grapefruit-juice-related safety/efficacy statements are not supported by the provided FDA label excerpts (notably bleeding risk, HDL/cardiovascular/antioxidant claims, numeric bioavailability claim, and absolute “no safe amount” counseling).
Suggested Improvement
Restrict grapefruit-juice claims to what the label excerpt supports: CYP3A4 inhibition and increased atorvastatin plasma concentrations, particularly with excessive grapefruit juice consumption (>1.2 liters/day). Remove unsupported assertions about bleeding, cardiovascular benefit/HDL, antioxidant effects, and unsupported numeric study results; avoid absolute safety statements not present in the provided label text.